
    
      A prospective, multicenter, "CE-approval cohort" analysis with the Symetis ACURATE TFâ„¢
      Transfemoral Aortic Bioprosthesis for minimal invasive implantation via transfemoral access
      to treat patients with severe aortic stenosis where conventional aortic valve replacement
      (AVR) via open heart surgery is considered to be associated with high risk, to evaluate the
      feasibility and performance of the implantation at 30-Days and at 1-Year Follow-up.
    
  